Objectives We evaluated the efficacy and safety of dalbavancin in ABSSSI and 'other sites' infections' (OTA). Methods Observational study involving 11 Italian hospitals including patients that received >= 1 dose of dalbavancin in 2016-2019. The outcome was end-of-treatment efficacy and safety in ABSSSI and OTA in a real-life setting. Results 206 patients enrolled (males 50%, median age 62 [IQR 50-76] years), 60.2% ABSSSI, 39.8% OTA. 69.7% ABSSSIvs90.7% OTA (p = 0.003) and 46.3% ABSSSIvs37.2% OTA (p = 0.786) received previous and concomitant antibiotics, respectively. 82.5% reached clinical cure . Eleven (5.4%) patients had non-serious adverse events (AE). OTA patients showed longer hospitalization (13.5 days, 5.5-22vs3, 0-11.7; p<0.0001) and received longer previous (18 days, 9-30vs11, 7-19; p = 0.007)/concomitant antibiotic treatments (21 days, 14-52vs11, 8-14; p < 0.0001), compared to ABSSSI. ABSSSI and OTA showed similar efficacy (85.5%vs75%, p = 0.459) and safety (no AE: 81.5%vs64.3%, p = 0.258); efficacy was independent of previous/concomitant therapies. Conclusions Dalbavancin demonstrated a success rate of >80%, with similar efficacy/safety in ABSSSI and off-label indications. The preferential use of dalbavancin as second-line or combination therapy would seem to suggest the need for in-depth studies focused on its off-label use.
Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study) / F. Bai, C. Aldieri, A. Cattelan, F. Raumer, E. Di Meco, M. Moioli, F. Tordato, P. Morelli, F. Borghi, M. Rizzi, E. Van Hauwermeiren, F. Castelli, G. Migliorino, B. Menzaghi, G. Rizzardini, A. Saracino, A. Cascio, M. Puoti, A. d'Arminio Monforte, G. Marchetti. - In: EXPERT REVIEW OF ANTI-INFECTIVE THERAPY. - ISSN 1478-7210. - 18:12(2020 Dec 01), pp. 1271-1279.
|Titolo:||Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study).|
BAI, FRANCESCA (Primo)
ALDIERI, CHIARA (Secondo)
D'ARMINIO MONFORTE, ANTONELLA (Penultimo)
MARCHETTI, GIULIA CARLA (Ultimo) [Writing – Review & Editing] (Corresponding)
|Parole Chiave:||Gram-positive infections; acute bacterial skin and skin structure infections; second-generation lipoglycopeptide antibiotics; dalbavancin;|
|Settore Scientifico Disciplinare:||Settore MED/17 - Malattie Infettive|
|Data di pubblicazione:||1-dic-2020|
|Data ahead of print / Data di stampa:||ago-2020|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1080/14787210.2020.1798227|
|Appare nelle tipologie:||01 - Articolo su periodico|
File in questo prodotto:
|Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections ABSSSIs and other infections in a real life.pdf||Publisher's version/PDF||Open Access Visualizza/Apri|